Devazepide, >=98% (HPLC), powder

Code: D3821-5MG D2-231

Application

Devazepide has been used as a cholecystokinin receptor 1 (CCK1R) antagonist in human embryonic kidney 293T cells and in human pancreatic slices.

Bio...


 Read more

Your Price
€193.58 5MG
€238.10 inc. VAT
REQUEST

Application

Devazepide has been used as a cholecystokinin receptor 1 (CCK1R) antagonist in human embryonic kidney 293T cells and in human pancreatic slices.

Biochem/physiol Actions

Devazepide is a CCK1 (CCK-A) receptor antagonist and a CCK8 antagonist.

Devazepide is a cholecystokinin octapeptide (CCK1) (CCK-A) receptor antagonist. It inhibits CCK binding to peripheral-type receptor (CCK-A). Devazepide reverses the cholecystokinin octapeptide (CCK-8) based antagonism towards morphine.

Features and Benefits

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

General description

Devazepide is derived from asperlicin by chemical modification and has the benzodiazepine backbone.

Packaging

5, 25 mg in glass bottle

assay≥98% (HPLC)
colorwhite to off-white
formpowder
InChI keyNFHRQQKPEBFUJK-HSZRJFAPSA-N
InChI1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)/t23-/m1/s1
originatorMerck & Co., Inc., Kenilworth, NJ, U.S.
Quality Level100
SMILES stringCN1C(=O)[C@@H](NC(=O)c2cc3ccccc3[nH]2)N=C(c4ccccc4)c5ccccc15
solubilityDMSO: >5 mg/mL
storage conditiondesiccated
storage temp.2-8°C
Cas Number103420-77-5
Hazard Class6.1
Un Number2811
Pack GroupI
This product has met the following criteria to qualify for the following awards:



PROCEED TO CHECKOUT

HAVE AN ACCOUNT? LOGIN
GUEST CHECKOUT

Proceed as a guest. You will have the option to register to access exclusive pricing and stock availability features after checkout.